HealthDay Reporter Read article
- Love the Smell of a Cup o’ Joe? Here’s What That Reveals About You
- For Women With HIV, Daily Life Can Impede Fight Against Virus
- AHA News: Drummer’s Death Inspires Grief-Stricken Bandmates to Rethink Rock ‘n’ Roll Lifestyle
- When E-Cig Makers Offer Promotional Items, More Teens Likely to Vape
- Prenatal Care App Can Reduce In-Person Obstetric Visits
- Colorectal Cancer Incidence Increasing in Younger Adults
- Heroin Overdose ED Visits Decreased From 2017 to 2018
Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of… Ted Lain, MD. Clinical trial investigator Dr. Ted Lain comments on the results of the OPAL study, a Phase 2b clinical trial which evaluated the efficacy of a novel topical gel formulation of the antibiotic minocycline (BPX-01) in reducing the number of inflammatory lesions in patients with moderate-to-severe inflammatory,… Elizabeth M. Swisher, MD. Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
Alzheimer’s disease (AD) is the most common cause of dementia in Western countries.
Great articles. learnt a lot from it.
Times Online / The Sunday Times voted Doctors Lounge as 3rd best ‘Ask an expert’ website.